An employee works in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444079

An employee works in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444078

Employees work in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444077

An employee works in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444076

An employee works in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444074

Employees work in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444073

Employees work in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444072

An employee works in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444071

From left, General Director of JSC "Pharmasintez" Evgeny Orachevsky, President of the group of companies "Pharmasintez" Vikram Punia and Governor of the Irkutsk region Igor Kobzev are pictured at the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444070

Governor of the Irkutsk region Igor Kobzev, left background, visits the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444069

the view shows the ampoules of the antiviral drug Rediform at the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444066

An employee works in the physical-chemical laboratory of quality control at the Russian drugmaker Pharmasyntez in Irkutsk, Russia. The first large shipment of the drug to combat COVID-19 "Rediform", a generic version of U.S. COVID-19 drug Remdesivir, is ready for release. Remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration in May after it was shown to shorten hospital stays for COVID-19 patients in a government-run clinical trial.

22.01.2021#6444060